BlueCrest Capital Management Ltd acquired a new stake in Colgate-Palmolive (NYSE:CL) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 23,995 shares of the company’s stock, valued at approximately $1,779,000.

Several other large investors also recently modified their holdings of the company. Pacer Advisors Inc. lifted its position in Colgate-Palmolive by 8.4% during the second quarter. Pacer Advisors Inc. now owns 20,224 shares of the company’s stock worth $1,499,000 after buying an additional 1,566 shares during the period. Alliancebernstein L.P. lifted its position in Colgate-Palmolive by 4.2% during the first quarter. Alliancebernstein L.P. now owns 1,899,356 shares of the company’s stock worth $139,014,000 after buying an additional 77,414 shares during the period. Israel Discount Bank of New York purchased a new position in Colgate-Palmolive during the first quarter worth about $1,349,000. Principal Financial Group Inc. lifted its position in Colgate-Palmolive by 0.6% during the first quarter. Principal Financial Group Inc. now owns 1,271,008 shares of the company’s stock worth $93,025,000 after buying an additional 7,905 shares during the period. Finally, Personal Capital Advisors Corp lifted its position in Colgate-Palmolive by 5.8% during the second quarter. Personal Capital Advisors Corp now owns 394,028 shares of the company’s stock worth $29,209,000 after buying an additional 21,456 shares during the period. Institutional investors and hedge funds own 72.96% of the company’s stock.

In other Colgate-Palmolive news, insider Victoria L. Dolan sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 9th. The stock was sold at an average price of $73.07, for a total transaction of $730,700.00. Following the completion of the sale, the insider now owns 60,528 shares in the company, valued at approximately $4,422,780.96. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Victoria L. Dolan sold 9,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $73.41, for a total value of $660,690.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 173,673 shares of company stock valued at $12,629,293. Insiders own 1.02% of the company’s stock.

Shares of Colgate-Palmolive (NYSE:CL) opened at $74.52 on Tuesday. The company has a quick ratio of 0.92, a current ratio of 1.23 and a debt-to-equity ratio of 24.42. Colgate-Palmolive has a 12 month low of $63.43 and a 12 month high of $77.27. The stock has a market capitalization of $64,136.80, a PE ratio of 25.45, a PEG ratio of 3.34 and a beta of 0.81.

Colgate-Palmolive (NYSE:CL) last posted its earnings results on Friday, October 27th. The company reported $0.73 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.73. Colgate-Palmolive had a return on equity of 2,782.56% and a net margin of 15.10%. The business had revenue of $3.97 billion during the quarter, compared to analyst estimates of $3.94 billion. During the same quarter last year, the firm earned $0.73 earnings per share. The company’s revenue for the quarter was up 2.8% compared to the same quarter last year. analysts expect that Colgate-Palmolive will post 2.88 EPS for the current year.

The business also recently announced a quarterly dividend, which was paid on Wednesday, November 15th. Stockholders of record on Monday, October 23rd were paid a $0.40 dividend. The ex-dividend date of this dividend was Friday, October 20th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.15%. Colgate-Palmolive’s dividend payout ratio (DPR) is currently 61.78%.

CL has been the topic of several recent analyst reports. Citigroup reduced their target price on Colgate-Palmolive from $76.00 to $75.00 and set a “neutral” rating on the stock in a research report on Thursday, November 2nd. Zacks Investment Research upgraded Colgate-Palmolive from a “hold” rating to a “buy” rating and set a $81.00 target price on the stock in a research report on Monday, October 23rd. KeyCorp reiterated a “hold” rating on shares of Colgate-Palmolive in a research report on Saturday, November 25th. SunTrust Banks upgraded Colgate-Palmolive from a “hold” rating to a “buy” rating and increased their target price for the stock from $65.00 to $85.00 in a research report on Wednesday, October 11th. Finally, Jefferies Group reiterated a “hold” rating and set a $79.00 target price on shares of Colgate-Palmolive in a research report on Thursday, September 28th. Two equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating and four have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $76.04.

WARNING: This piece of content was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://theolympiareport.com/2017/12/05/bluecrest-capital-management-ltd-takes-position-in-colgate-palmolive-cl.html.

Colgate-Palmolive Profile

Colgate-Palmolive Company (Colgate) is a consumer products company. The Company operates in two product segments: Oral, Personal and Home Care, and Pet Nutrition. The Oral, Personal and Home Care product segment is operated through five geographic segments, which include North America, Latin America, Europe, Asia Pacific and Africa/Eurasia.

Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive (NYSE:CL).

Institutional Ownership by Quarter for Colgate-Palmolive (NYSE:CL)

Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with Analyst Ratings Network's FREE daily email newsletter.